Breast cancer has been historically sub-classified on the basis of three molecular markers; estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (EGFR2/Her2), whose presence/absence guide the prognosis and therapeutic interventions. This evidence concerns the gene PGR and breast carcinoma.